{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:00:42Z","timestamp":1757779242437,"version":"3.37.3"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>Adverse Event<\/jats:title><jats:p>Decreased abiraterone exposure after introducing carbamazepine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Drugs Implicated<\/jats:title><jats:p>Abiraterone acetate and carbamazepine.<\/jats:p><\/jats:sec><jats:sec><jats:title>The Patient<\/jats:title><jats:p>A 65\u2010year\u2010old man with metastatic castration resistant prostate cancer, was treated with abiraterone acetate and prednisolone, and received concomitant carbamazepine for treatment of facial neuropathy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Evidence that Links the Drug to the Event<\/jats:title><jats:p>The interaction was confirmed by a decrease in abiraterone exposure &gt;2\u2010fold (area\u2010under\u2010the\u2010curve and trough levels). After discontinuation of carbamazepine therapy, the abiraterone exposure normalized. No alternative causes were found that explain the decrease in abiraterone exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Mechanism<\/jats:title><jats:p>Induction of CYP3A and potentially phase I metabolism (SULT2A1) by carbamazepine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for Therapy<\/jats:title><jats:p>Clinicians and pharmacists should be aware of this clinically relevant interaction. The national drug\u2013drug interaction checker does not warn for this interaction, whereas both the Lexicomp\u00ae and Micromedex\u00ae advice to avoid if possible or to increase the abiraterone dose frequency to twice daily. Carbamazepine should not be combined with abiraterone to avoid underexposure and suboptimal therapy. Therapeutic drug monitoring of abiraterone is useful to guide therapy when drug\u2013drug interactions cannot be avoided.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13532","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T22:32:17Z","timestamp":1517437937000},"page":"1064-1067","source":"Crossref","is-referenced-by-count":6,"title":["A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration\u2010resistant metastatic prostate cancer"],"prefix":"10.1111","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-3575","authenticated-orcid":false,"given":"Guillemette E.","family":"Benoist","sequence":"first","affiliation":[{"name":"Department of Pharmacy Radboud Institute for Health Sciences, Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8754-1210","authenticated-orcid":false,"given":"Maarten J.","family":"van der Doelen","sequence":"additional","affiliation":[{"name":"Department of Urology Radboud Institute for Health Sciences, Radboud University Medical Center  Nijmegen The Netherlands"},{"name":"Department of Medical Oncology Radboud Institute for Health Sciences, Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-8201","authenticated-orcid":false,"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Radboud Institute for Health Sciences, Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Radboud Institute for Health Sciences, Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-1831","authenticated-orcid":false,"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Radboud Institute for Health Sciences, Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,21]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0178-6"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0425-0"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1549"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.11.027"},{"key":"e_1_2_3_8_1","unstructured":"EMA.European Public Assessment Report (EPAR) Zytiga (abiraterone acetate)2011[updated 20\/11\/2017. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002321\/WC500112858.pdf."},{"key":"e_1_2_3_9_1","unstructured":"FDA. US Food and Drug Administration.Prescribing information Zytiga (abiraterone acetate) tablets [Prescribing Information].2011[updated April 2017. Available from:https:\/\/www.zytiga.com\/shared\/product\/zytiga\/zytiga\u2010prescribing\u2010information.pdf."},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3291-z"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.132"},{"key":"e_1_2_3_12_1","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3986","article-title":"Analytical challenges in quantifying abiraterone with LC\u2010MS\/MS in human plasma","volume":"31","author":"Benoist GE","year":"2017","journal-title":"Biomed Chromatogr"},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H423"},{"key":"e_1_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.08.013"},{"key":"e_1_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0396-1"},{"key":"e_1_2_3_16_1","article-title":"Evaluation of tobramycin exposure predictions in three Bayesian forecasting programmes compared with current clinical practice in children and adults with cystic fibrosis","author":"Burgard M","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_3_17_1","unstructured":"FDA. US Food and Drug Administration.Clinical pharmacology and biopharmaceutics review Zytiga (Abiraterone Acetate).2010:1\u201086."},{"key":"e_1_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13425"},{"key":"e_1_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13877"},{"key":"e_1_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13880"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13532","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:06:41Z","timestamp":1695546401000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,21]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/bcp.13532"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13532","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2018,2,21]]}}}